Ovarian Cancer: Global Clinical Trial Landscape - Focus On Asia Pacific

A tumor will gradually form as abnormal cells start growing and dividing uncontrollably. When this occurs in a female’s ovaries, the growth can sometimes lead to the development of ovarian cancer (OC). According to reports, epithelial ovarian cancer is the most frequent kind of ovarian cancer.¹ In 2020, OC was cited as the third most prevalent gynaecological cancer in the world and currently ranks as the eighth most common cancer diagnosed worldwide. Among other types of gynaecology cancers, OC is the second leading cause of mortality, despite extensive use of conventional and contemporary technology for OC detection and prognosis.²

When diagnosed, the National Comprehensive Cancer Network (NCCN) recommends surgery as the initial treatment followed by systemic chemotherapy in the majority of patients.¹⁰ Since 2016, however, biopharma companies have initiated over 1,600 ongoing clinical trials in OC, with the Asia Pacific region involved in approximately 30% of the trials.

Better understand the incidence, distribution, and possible control of OC in the Asia Pacific region, the standard of care, trial landscape, and more by accessing this report.